Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)

Key facts

Sponsor

Koneti Rao

Principal Investigator

Koneti Rao, MD

DIR, NIAID, NIH

Intervention

Valproic Acid(drug)

Enrollment

6 enrolled

Eligibility

2-70 years · All sexes

Timeline

2008 – 2011

Study locations (1)

• National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Autoimmune lymphoproliferative syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT03328650
  Clinical Outcomes of the ALPS Proximal Humerus Plating System
  Vanderbilt University Medical Center

See all trials for Autoimmune lymphoproliferative syndrome →